Humulin R U-500 Kwikpen (insulin regular, human)
Short-Acting Insulins Subcutaneous Insulin Pen (ML)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Insulin human is a biosynthetic protein that is structurally identical to endogenous insulin secreted by the beta cells of the human pancreas; commercially available insulin human preparations are classified as short-acting (insulin human (regular)) or intermediate-acting (isophane insulin human).
Insulin human is a biosynthetic protein that is structurally identical to endogenous insulin secreted by the beta cells of the human pancreas. Although structurally identical to endogenous human insulin, commercially available insulin human is not extracted from the human pancreas, but is prepared biosynthetically from cultures of genetically modified Escherichia coli or Saccharomyces cerevisiae. Biosynthetic insulin human (Humulin(R)) is prepared using recombinant DNA technology and special laboratory strains of nonpathogenic E. coli; the A and B chains of human insulin are synthesized by different strains of E. coli.
The bacteria have been genetically modified by the addition of plasmids that incorporate genes for human insulin synthesis. Biosynthetic insulin human (Novolin(R) (formerly available as semisynthetic insulin)) is prepared using recombinant DNA technology and strains of Saccharomyces cerevisiae. Unlike the process used for the production of animal insulins (no longer commercially available in the US), the commercial process using recombinant DNA technology to produce insulin human avoids contamination with glucagon, somatostatin, and proinsulin.
Although a possible theoretical source of protein contamination (i.e., E. coli polypeptides (ECPs)) of certain biosynthetic insulin human (i.e., Humulin(R)) could be derived from the E. coli organism used in its manufacture, this commercially available biosynthetic insulin human contains less than 4 ppm of immunoreactive ECPs. Insulin human lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting glucose production. Insulin human also inhibits lipolysis and proteolysis and enhances protein synthesis.
After subcutaneous injection of insulin human (regular), the pharmacologic effect begins approximately 30 minutes (range: 10--75 minutes). The onset of action is more rapid when administered IV (approximately 10--15 minutes). In healthy subjects given subcutaneous insulin regular, peak insulin concentrations occurred between 36--150 minutes (Humulin(R) R) and 1.5--2.5 hours (Novolin(R) R) after dosing.
The peak insulin level of concentrated (U-500) insulin human regular occurs between 4--8 hours (range: 0.5--8 hours) after subcutaneous administration in healthy obese individuals. After subcutaneous administration of isophane insulin human, the median peak serum concentration occurred at approximately 4 hours (range: 1--12 hours). After oral inhalation of insulin human, the time to maximum serum insulin concentrations ranged from 10--20 minutes.
The absolute bioavailability of insulin human (regular) ranges from 48--89% after subcutaneous injection. Uptake and degradation of insulin human predominantly occurs in the liver, kidney, muscle, and adipocytes, with the liver being the major organ involved in clearance of insulin. After subcutaneous administration, the median half-life of insulin human is approximately 1.5 hours (range: 40 minutes--7 hours); with higher doses (50 and 100 units), the half-life was 3.6 hours.
The mean half-life of concentrated (U-500) insulin human in obese subjects is approximately 4.5 hours (range: 1.9--10 hours). When insulin human (regular) is administered IV, the mean half-life is 20 minutes after a dose of 0.1 units/kg and 1 hour after a dose of 0.2 units/kg. In obese subjects who received 50 and 100 unit subcutaneous doses, the mean time of termination of effect was prolonged to approximately 18 hours (range: 12--24 hours).
In healthy subjects given isophane insulin human, the mean half-life was approximately 4.4 hours (range: 1--84 hours). The half-life of insulin human dry powder for inhalation ranges from 120--206 minutes; serum concentrations declined to baseline by approximately 60--240 minutes. Carrier particles used in insulin human dry powder for inhalation are not metabolized and are eliminated unchanged in the urine following absorption from the lungs.
The time course of action (i.e., glucose lowering) may vary considerably in different individuals or within the same individual and with different doses. Manufacturers of some insulin human products state that the effects of gender, age, obesity, renal, and hepatic impairment on the pharmacokinetics of insulin human have not been studied. The rate of absorption and onset of activity is known to be affected by the site of injection, exercise, and other variables.
USES: Concentrated insulin regular is used with a proper diet and exercise program to control high blood sugar in people with diabetes who require large doses of insulin (more than 200 units per day). Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke.
This man-made insulin product is the same as human insulin. It replaces the insulin that your body would normally make. It works right away like regular insulin but its effects last longer.
It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication may be used alone or with other oral diabetes drugs (such as metformin).
Generic name: insulin regular, human
Pronunciation: (IN-su-lin)
Drug class: Short-Acting Insulins
Therapeutic class: Endocrine
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Humulin R U-500 Kwikpen
Indications
The following indications are listed for Humulin R U-500 Kwikpen:
- Diabetes Mellitus With Severe Insulin Resistance
Dosing
Dosage of insulin human is always expressed in USP units.
Dosage of insulin should be individualized based on the route of administration, the patient's metabolic needs, blood glucose monitoring results, and glycemic control goal to attain optimum therapeutic effect. Dosage modifications may be needed with changes in physical activity, changes in meal patterns (e.g., macronutrient content, timing of food intake), changes in renal or hepatic function, or during acute illness.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Agents Affecting Growth Hormone/Macimorelin
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Agents affecting growth hormone may impact the accuracy of the macimorelin diagnostic test.(1)
CLINICAL EFFECTS: Concurrent use of agents affecting growth hormone may impact the accuracy of the macimorelin diagnostic test.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The US manufacturer of macimorelin states concurrent use with agents affecting growth hormone may impact the accuracy of the macimorelin diagnostic test. Discontinue growth hormone products at least 1 week before administering the macimorelin diagnostic test. Sufficient washout time of drugs affecting growth hormone release prior to administration of macimorelin is recommended.(1) Agents affecting growth hormone include: - Drugs that directly affect the pituitary secretion of growth hormone (e.g. somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors) - Drugs that may transiently elevate growth hormone concentrations (e.g. clonidine, levodopa, insulin) - Drugs that may blunt the growth hormone response (e.g. muscarinic antagonists, anti-thyroid medications, growth hormone products)
DISCUSSION: Concurrent use of agents affecting growth hormone may impact the accuracy of the macimorelin diagnostic test.(1)
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Antidiabetic Agents/Gatifloxacin
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The exact mechanism is unknown.
CLINICAL EFFECTS: Concurrent use of gatifloxacin may result in hypoglycemia and/or hyperglycemia.(1-4) Hypoglycemia is more common during the first three days of concurrent therapy. Hyperglycemia is more common after the first three days of concurrent therapy.(2)
PREDISPOSING FACTORS: Elderly patients, especially those with decreased renal function may be predisposed to this interaction.(2)
PATIENT MANAGEMENT: Patients receiving concurrent gatifloxacin should be closely monitored for hypoglycemia during the first three days of concurrent therapy and for hyperglycemia after the first three days of concurrent therapy. Patients should be instructed to discontinue gatifloxacin if hypoglycemia or hyperglycemia occur.(2)
DISCUSSION: Hypoglycemia has been reported with gatifloxacin and glyburide(1,5,6) or glimepiride.(7) In a study in patients with type 2 diabetes mellitus, concurrent gatifloxacin (400 mg daily for 10 days) had no effect on the pharmacokinetics of glyburide (steady state daily regimen); however, pharmacodynamic interactions have been reported.(2) Health Canada has received 19 reports of hypoglycemia in patients taking gatifloxacin. Seventeen of these involved concurrent hypoglycemic agents. Health Canada has received 2 reports of hyperglycemia in patients taking gatifloxacin and hypoglycemic agents. Health Canada has received 2 reports of patients experiencing hypoglycemia and hyperglycemia during concurrent gatifloxacin and hypoglycemic agents.(3) In a study, 13 reports of dysglycemia were reported in patients taking gatifloxacin. Ten of these patients had diabetes mellitus and were on concurrent hypoglycemic agents. Of these ten patients, nine patients experienced hypoglycemia, while one patient experienced hyperglycemia.(8)
Insulin/Rosiglitazone
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The exact mechanism is unknown, but may be the result of additive fluid retention.(1,2)
CLINICAL EFFECTS: The concurrent use of rosiglitazone and insulin may increase the risk of edema, heart failure, and other cardiovascular effects such as myocardial infarction.(1,2)
PREDISPOSING FACTORS: Use in patients with NYHA Class I and II heart failure may increase the risk of other cardiovascular events.(1,2)
PATIENT MANAGEMENT: The US manufacturer of rosiglitazone states that concurrent use with insulin is not recommended.(1) If concurrent therapy is warranted, patients should be monitored for cardiovascular adverse events. If signs and symptoms of congestive heart failure develop, patients should be treated according to current standards of care. Consideration should be given to lowering the dosage of or discontinuing rosiglitazone.(2)
DISCUSSION: In a meta-analysis of 7 controlled, randomized, double-blind clinical trials in which patients were randomized to coadministration of rosiglitazone with insulin or insulin alone, the incidence of congestive heart failure in patients receiving concurrent rosiglitazone was 2.3%, compared with 1.0% in patients receiving insulin alone. More patients in the concurrent rosiglitazone group experienced myocardial infarctions, MACE (a composite of myocardial infarction, cardiovascular death, or stroke), cardiovascular deaths, and all-cause deaths than in the group receiving insulin alone.(1) In clinical trials, edema was reported in 14.7% of patients receiving concurrent rosiglitazone and insulin, compared with 5.4% on insulin alone or 4.8% on rosiglitazone alone.(1) In clinical trials, new onset or exacerbation of congestive heart failure occurred at rates of 1%, 2%, and 3%, respectively, in patients treated with insulin alone, insulin with 4 mg of rosiglitazone, and insulin with 8 mg of rosiglitazone.(1)
Moderate Interaction: Assess the risk to the patient and take action as needed.
Antidiabetic Agents/Gymnema
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Gymnema has been shown to increase the number of insulin-secreting beta cells in animals. It has also been shown to increase the activity of enzymes responsible for glucose uptake and utilization and inhibit peripheral utilization of glucose.(1)
CLINICAL EFFECTS: Use of gymnema may result in decreased requirements of antidiabetic agents.(2-4)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Diabetic patients should be carefully monitored if gymnema is initiated or discontinued from concurrent therapy. The dosage of the patient's antidiabetic agent(s) may need to be adjusted.(2)
DISCUSSION: In a study in 22 non-insulin-dependent patients, patients had decreased blood glucose, glycosylated hemoglobin, and glycosylated plasma proteins during gymnema therapy. Patients were able to decrease the dosage of their conventional antidiabetic therapy and five patients were able to discontinue their conventional antidiabetic therapy.(3) In a study in 27 insulin-dependent patients, patients had decreased insulin requirements, fasting blood glucose, glycosylated hemoglobin, and glycosylated plasma protein levels.(4)
Antidiabetics/Epinephrine
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Gluconeogenesis, glycogenolysis, and lipolysis are increased by epinephrine. Also, insulin secretion and glucose uptake by peripheral tissues are decreased by epinephrine.
CLINICAL EFFECTS: Increased blood glucose resulting in decreased effectiveness of the antidiabetic agent.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Caution when starting or stopping epinephrine in diabetic patients. Adjust the antidiabetic dose as needed based on blood glucose levels.
DISCUSSION: This interaction is likely to occur based upon well documented properties of the interacting drugs. However, there is individual variability in its occurrence.
Antidiabetics/Slt Ophth Non-Cardioselective Beta-Blockers
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Not fully established. Probably blockade of a variety of beta-adrenergic responses to hypoglycemia.(1,2)
CLINICAL EFFECTS: Diminished response to sulfonylureas and insulin may occur. Frequency and severity of hypoglycemic episodes may be increased, while warning symptoms of low blood sugar may be masked.(1,2)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Try to avoid beta-blocker therapy, particularly in diabetics prone to hypoglycemic attacks. One of the cardioselective agents may decrease risk of hypertensive attacks and allow more rapid glucose recovery from hypoglycemia. Patients should be counseled not to rely on tachycardia to diagnose hypoglycemia, since it is masked by beta-blocker therapy. Diaphoresis is unaffected by beta-blockade and can be used by the diabetic to recognize hypoglycemia.
DISCUSSION: A double blind, randomized, 12 month study of 39 patients tested the metabolic effects of pindolol (5mg BID) compared to control group on insulin sensitivity. The patient's insulin sensitivity index decreased 17% when on pindolol treatment compared to placebo (p<0.01). Insulin mediated glucose uptake was significantly lower (p<0.05) with propranolol treatment than with placebo.(3) A study of 26 patients with chronic heart failure showed that carvedilol (average daily dose 27.5mg/d) caused a significant decrease in fasting insulin levels (17.09 to 10.77 microU/ml, p <0.05) compared to pre-treatment levels. This trial also showed that patients on carvedilol had significantly (p=0.015) lower fasting insulin levels (10.77 microU/ml) compared to the fasting insulin levels (20.72 microU/ml) of patients on bisoprolol treatment (5.9mg/d).(4) There have been case reports of hypoglycemia following the addition of ophthalmic timolol to a diabetic regimen.(5-7) Studies have shown that ophthalmic beta-blockers, especially the aqueous solution, have significant systemic absorption and do not undergo first-pass metabolism.(8,9)
Hypoglycemics; Insulin/Bupropion
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Bupropion can lower the seizure threshold and when given concurrently with other medications that also lower the threshold there is an increased risk of seizure. Concurrent use of hypoglycemics or insulin increases the risk of hypoglycemia which can result in seizures.(1,2)
CLINICAL EFFECTS: Concurrent use of bupropion and hypoglycemics or insulin may increase the risk of seizure.(1,2)
PREDISPOSING FACTORS: The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants an anorectics; a total daily dose of bupropion greater than 450 mg or single doses greater than 150 mg; rapid escalation of bupropion dosage; or with concomitant medications known to lower seizure threshold (antidepressants, antipsychotics, systemic steroids, theophylline).(1,2)
PATIENT MANAGEMENT: The use of bupropion in patients treated with oral hypoglycemic agents or insulin should be undertaken only with extreme caution and with low initial bupropion dosing and small gradual dosage increases.(1,2) Single doses should not exceed 150 mg.(1,2) The maximum daily dose of bupropion should not exceed 300 mg for smoking cessation(2) or 450 mg for depression.(1)
DISCUSSION: Because of the risk of seizure from concurrent bupropion and other agents that lower seizure threshold, the manufacturer of bupropion states that the concurrent use of bupropion and oral hypoglycemic agents or insulin should be undertaken only with extreme caution and with low initial bupropion dosing and small gradual dosage increases.(1,2)
Insulin/Carvedilol; Labetalol
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Not fully established. Probably blockade of a variety of beta-adrenergic responses to hypoglycemia.
CLINICAL EFFECTS: Diminished response to insulin may occur. Frequency and severity of hypoglycemic episodes may be increased, while warning symptoms of low blood sugar may be masked.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Try to avoid beta-blocker therapy, particularly in diabetics prone to hypoglycemic attacks. One of the cardioselective agents may decrease risk of hypertensive attacks and allow more rapid glucose recovery from hypoglycemia. Patients should be counseled not to rely on tachycardia to diagnose hypoglycemia, since it is masked by beta-blocker therapy. Diaphoresis is unaffected by beta-blockade and can be used by the diabetic to recognize hypoglycemia.
DISCUSSION: A class effect of diminished glucose-lowering effects is expected with concurrent use of beta-blockers and insulin. It is prudent to monitor serum glucose closely in patients receiving beta-blocker therapy because symptoms of hypoglycemia may be masked. A double blind, randomized, 12 month study of 39 patients tested the metabolic effects of pindolol (5 mg BID) compared to control group on insulin sensitivity. The patient's insulin sensitivity index decreased 17% when on pindolol treatment compared to placebo (p<0.01). Insulin mediated glucose uptake was significantly lower (p<0.05) with propranolol treatment than with placebo. (1) A study of 26 patients with chronic heart failure showed that carvedilol (average daily dose 27.5 mg/d) caused a significant decrease in fasting insulin levels (17.09 to 10.77 microU/ml, p <0.05) compared to pre-treatment levels. This trial also showed that patients on carvedilol had significantly (p=0.015) lower fasting insulin levels (10.77 microU/ml) compared to the fasting insulin levels (20.72 microU/ml) of patients on bisoprolol treatment (5.9mg/d).(2)
Insulin/Fenfluramine;Dexfenfluramine
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Fenfluramine increases glucose uptake at the receptor site (ie, skeletal muscle).
CLINICAL EFFECTS: The hypoglycemic effect of insulin is increased.
PREDISPOSING FACTORS: Diabetes.
PATIENT MANAGEMENT: In diabetic patients receiving insulin, monitor blood glucose levels and observe the patient for signs of hypoglycemia when initiating therapy with fenfluramine and for symptoms of hyperglycemia when fenfluramine is discontinued.
DISCUSSION: When administered before meals or to fasting patients, fenfluramine has been found to have hypoglycemic action. Numerous reports have demonstrated fenfluramine to potentiate the hypoglycemic effect of insulin in diabetic patients.
Insulin/Pioglitazone
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The exact mechanism is unknown, but may be the result of additive fluid retention.(1,2)
CLINICAL EFFECTS: The concurrent use of pioglitazone with insulin may increase the risk of edema and heart failure.(1,2)
PREDISPOSING FACTORS: Specific risk factors for heart failure could not be determined. Patients with ongoing edema are more likely to have edema-associated adverse effects with combination therapy.(1)
PATIENT MANAGEMENT: Patients receiving concurrent therapy should be monitored for cardiovascular adverse events. If signs and symptoms of congestive heart failure develop, patients should be treated according to current standards of care. Consideration should be given to lowering the dosage of or discontinuing pioglitazone.(1,2)
DISCUSSION: In a clinical trial, two of 191 (1.1%) of patients receiving pioglitazone (15 mg) and insulin and two of 188 (1.1%) of patients receiving pioglitazone (30 mg) and insulin developed congestive heart failure. None of the patients receiving insulin alone developed congestive heart failure.(1)
Insulin/Selected Systemic Non-Cardioselective Beta-Blockers
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Not fully established. Probably blockade of a variety of beta-adrenergic responses to hypoglycemia. MECHANISM OF ACTION: Not fully established. Probably blockade of a variety of beta-adrenergic responses to hypoglycemia.
CLINICAL EFFECTS: Diminished response to insulin may occur. Frequency and severity of hypoglycemic episodes may be increased, while warning symptoms of low blood sugar may be masked. CLINICAL EFFECTS: Diminished response to insulin may occur. Frequency and severity of hypoglycemic episodes may be increased, while warning symptoms of low blood sugar may be masked.
PREDISPOSING FACTORS: None determined. PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Try to avoid beta-blocker therapy, particularly in diabetics prone to hypoglycemic attacks. One of the cardioselective agents may decrease risk of hypertensive attacks and allow more rapid glucose recovery from hypoglycemia. Patients should be counseled not to rely on tachycardia to diagnose hypoglycemia, since it is masked by beta-blocker therapy. Diaphoresis is unaffected by beta-blockade and can be used by the diabetic to recognize hypoglycemia. PATIENT MANAGEMENT: Try to avoid beta-blocker therapy, particularly in diabetics prone to hypoglycemic attacks. One of the cardioselective agents may decrease risk of hypertensive attacks and allow more rapid glucose recovery from hypoglycemia. Patients should be counseled not to rely on tachycardia to diagnose hypoglycemia, since it is masked by beta-blocker therapy. Diaphoresis is unaffected by beta-blockade and can be used by the diabetic to recognize hypoglycemia.
DISCUSSION: A class effect of diminished glucose-lowering effects is expected with concurrent use of beta-blockers and insulin. It is prudent to monitor serum glucose closely in patients receiving beta-blocker therapy because symptoms of hypoglycemia may be masked. A double blind, randomized, 12 month study of 39 patients tested the metabolic effects of pindolol (5 mg BID) compared to control group on insulin sensitivity. The patient's insulin sensitivity index decreased 17% when on pindolol treatment compared to placebo (p<0.01). Insulin mediated glucose uptake was significantly lower (p<0.05) with propranolol treatment than with placebo. (1) A study of 26 patients with chronic heart failure showed that carvedilol (average daily dose 27.5 mg/d) caused a significant decrease in fasting insulin levels (17.09 to 10.77 microU/ml, p <0.05) compared to pre-treatment levels. This trial also showed that patients on carvedilol had significantly (p=0.015) lower fasting insulin levels (10.77 microU/ml) compared to the fasting insulin levels (20.72 microU/ml) of patients on bisoprolol treatment (5.9mg/d).(2) DISCUSSION: A class effect of diminished glucose-lowering effects is expected with concurrent use of beta-blockers and insulin. It is prudent to monitor serum glucose closely in patients receiving beta-blocker therapy because symptoms of hypoglycemia may be masked. A double blind, randomized, 12 month study of 39 patients tested the metabolic effects of pindolol (5 mg BID) compared to control group on insulin sensitivity. The patient's insulin sensitivity index decreased 17% when on pindolol treatment compared to placebo (p<0.01). Insulin mediated glucose uptake was significantly lower (p<0.05) with propranolol treatment than with placebo. (1) A study of 26 patients with chronic heart failure showed that carvedilol (average daily dose 27.5 mg/d) caused a significant decrease in fasting insulin levels (17.09 to 10.77 microU/ml, p <0.05) compared to pre-treatment levels. This trial also showed that patients on carvedilol had significantly (p=0.015) lower fasting insulin levels (10.77 microU/ml) compared to the fasting insulin levels (20.72 microU/ml) of patients on bisoprolol treatment (5.9mg/d).(2)
Selected Antidiabetic Agents/Chloroquine; Hydroxychloroquine
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The exact mechanism is unknown. Chloroquine and hydroxychloroquine may increase insulin sensitivity by inhibiting insulin metabolism and inflammation and increasing cellular uptake of glucose and glycogen synthesis.(1,2) These effects may result in additive hypoglycemia with anti-diabetic agents.
CLINICAL EFFECTS: Concurrent use of chloroquine or hydroxychloroquine and antidiabetic agents may result in severe hypoglycemia.(3) Hypoglycemia can lead to coma.
PREDISPOSING FACTORS: Elderly patients, especially those with decreased renal function may be predisposed to this interaction.
PATIENT MANAGEMENT: Patients maintained on antidiabetic agents who require concurrent therapy with chloroquine or hydroxychloroquine should be closely monitored for hypoglycemia. A decrease in the dose of insulin or other anti-diabetic medications may be required. Patients should be advised of the risk and symptoms of hypoglycemia and to contact their doctor if hypoglycemia occurs.(3) Signs of hypoglycemia may include confusion, dizziness, feeling shaky, unusual hunger, headaches, irritability, pounding heart or very fast pulse, pale skin, sweating, trembling, weakness, or unusual anxiety.
DISCUSSION: Hydroxychloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening.(3) Concomitant hypoglycemic agents may increase the risk and/or severity of this effect. A 77 year old man who was stable on twice daily insulin suffered two episodes of hypoglycemic coma 2 weeks after starting prednisone 5 mg daily and hydroxychloroquine 400 mg daily for rheumatoid arthritis. His insulin dosage required a decrease of 37%.(4) Many studies have investigated the glucose-lowering effect of hydroxychloroquine. In a clinical trial of type II diabetics on maximal doses of sulfonylureas, addition of hydroxychloroquine lowered hemoglobin A1C (HbA1C) up to 1% more than placebo.(5) Another clinical trial of type II diabetics on metformin and glimepiride or gliclazide found that hydroxychloroquine 400 mg daily reduced fasting blood glucose (FBG), post-prandial glucose (PPG), and HbA1C to a similar degree as pioglitazone 15 mg daily at 24 weeks.(6) In a prospective observational study, 250 uncontrolled type II diabetics on metformin, glimepiride, pioglitazone, sitagliptin, and a SGLT-2 inhibitor received hydroxychloroquine 400 mg daily for 48 weeks. HbA1C decreased from 8.83% to 6.44%, FBG decreased by 40.78%, and PPG decreased by 58.95%. The doses of metformin were reduced by 50%, glimepiride and sitagliptin by 75%, and SGLT-2 inhibitors were discontinued in most patients.(7)
Selected Antidiabetic Agents/Selected Quinolones
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The exact mechanism is unknown.
CLINICAL EFFECTS: Concurrent use of quinolones and antidiabetic agents may result in severe hypoglycemia.(1-7) Hypoglycemia can lead to coma.
PREDISPOSING FACTORS: Elderly patients, especially those with decreased renal function may be predisposed to this interaction.(5)
PATIENT MANAGEMENT: Patients maintained on antidiabetic agents who require concurrent therapy with a quinolone should be closely monitored for hypoglycemia.(1-4) Patients should be instructed to discontinue quinolone use and contact their doctor if hypoglycemia occurs.(2,4) Signs of hypoglycemia may include confusion, dizziness, feeling shaky, unusual hunger, headaches, irritability, pounding heart or very fast pulse, pale skin, sweating, trembling, weakness, or unusual anxiety.
DISCUSSION: Hypoglycemia has been reported with concurrent ciprofloxacin and glyburide,(1,8,9) levofloxacin and glyburide,(2,10,11) norfloxacin and glyburide,(3) levofloxacin and glipizide (12) as well as levofloxacin and metformin-glibenclamide.(14) There has been one report of fatal hypoglycemia with concurrent levofloxacin and glyburide(9) and one of the above reports of hypoglycemia with concurrent levofloxacin and glyburide resulted in hypoxic brain injury.(11) A review of postmarketing adverse event data for the fluoroquinolones and hypoglycemic coma identified 56 reports in FAERS search from October 1987- April 2017 and 11 additional cases in the medical literature. Most patients had risk factors for hypoglycemia. 41 patients were taking one or more hypoglycemic drugs. 13 deaths occurred (some of these patients had renal insufficiency). 9 patients did not fully recover and had resultant disability.(13)
Selected Antidiabetics/Maois
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The exact mechanism by which MAO inhibitors affect carbohydrate metabolism and subsequent enhancement of the hypoglycemic action of insulin is not clear. The adrenergic response to hypoglycemia may be blocked by insulin release caused by MAOI's. In vitro studies have shown that MAO inhibitors are capable of both potentiating and inhibiting insulin release, depending on their concentrations. Stimulation of glucose-mediated insulin secretion is believed to be related to the MAO inhibitory effects of the drugs.
CLINICAL EFFECTS: The hypoglycemic response to both insulin and glucose lowering agents including alpha glucosidase inhibitors, meglitinides, and sulfonylurea may be increased.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Concurrent MAO inhibitor therapy for depression in a diabetic patient will often require reduction in dosage of the hypoglycemic agent because of enhanced hypoglycemic effects. Since the extent of the reaction is highly unpredictable, any diabetic patients receiving MAO inhibitors should be monitored for possible excessive hypoglycemia.
DISCUSSION: This interaction is likely to occur. The interaction between MAOIs and insulin is well documented. Additional documentation is necessary to confirm the potential interaction of MAOI's with other glucose lowering agents including alpha glucosidase inhibitors, meglitinides, and sulfonylureas but is expected to occur based on pharmacologic similarity. It may take several weeks for the full hypoglycemic effect of the MAOI to occur. Conversely, it may take several weeks for the effect to dissipate after stopping the MAOI. Furazolidone is known to be a monoamine oxidase inhibitor. Methylene blue, when administered intravenously, has been shown to reach sufficient concentrations to be a potent inhibitor of MAO-A. Metaxalone is a weak inhibitor of MAO.
Selected Antidiabetics/Safinamide
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The exact mechanism by which MAO inhibitors such as safinamide affect carbohydrate metabolism and subsequent enhancement of the hypoglycemic action of insulin is not clear. The adrenergic response to hypoglycemia may be blocked by insulin release caused by MAOI's. In vitro studies have shown that MAO inhibitors are capable of both potentiating and inhibiting insulin release, depending on their concentrations. Stimulation of glucose-mediated insulin secretion is believed to be related to the MAO inhibitory effects of the drugs.
CLINICAL EFFECTS: The hypoglycemic response to both insulin and glucose lowering agents including alpha glucosidase inhibitors, meglitinides, and sulfonylurea may be increased.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Concurrent MAO inhibitor therapy for depression in a diabetic patient will often require reduction in dosage of the hypoglycemic agent because of enhanced hypoglycemic effects. Since the extent of the reaction is highly unpredictable, any diabetic patients receiving MAO inhibitors should be monitored for possible excessive hypoglycemia.
DISCUSSION: This interaction is likely to occur. The interaction between MAOIs and insulin is well documented. Additional documentation is necessary to confirm the potential interaction of MAOI's with other glucose lowering agents including alpha glucosidase inhibitors, meglitinides, and sulfonylureas but is expected to occur based on pharmacologic similarity. It may take several weeks for the full hypoglycemic effect of the MAOI to occur. Conversely, it may take several weeks for the effect to dissipate after stopping the MAOI.
Contraindications
*Contraindicated during episodes of hypoglycemia.
*Hypersensitivity to insulin human or any of its excipients.
*For insulin human dry powder for inhalation, contraindicated in chronic lung disease, such as asthma or chronic obstructive pulmonary disease (COPD), because of the risk of acute bronchospasm.
There are no contraindication contraindications for this drug.
- Hypoglycemic disorder
- Disease of liver
- Hypokalemia
- Kidney disease with reduction in glomerular filtration rate (GFr)
Adverse reactions
The most common adverse reactions observed with insulin human (regular) include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, weight gain, edema, pruritus, and rash.
The most common adverse reactions observed with isophane insulin human include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, weight gain, and edema.
The most common adverse reactions observed with isophane insulin human in fixed combination with insulin human include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, weight gain and edema.
The most common adverse reactions associated with insulin human dry powder for inhalation (>=2% of patients) include hypoglycemia, cough, and throat pain or irritation.
More Frequent
- Hypoglycemic disorder
Rare or Very Rare
- Anaphylaxis
- Edema
- Hypokalemia
More Frequent
- Injection site sequelae
- Weight gain
Less Frequent
- Lipodystrophy
Precautions
No enhanced messaging available.
Most commercially available insulin human products are indicated to improve glycemic control in pediatric patients with diabetes mellitus. The dosage of insulin human must be individualized in pediatric patients based on metabolic needs and frequent monitoring of blood glucose to minimize the risk of hypoglycemia. Safety and effectiveness of insulin human regular U-500 in pediatric patients requiring more than 200 units of insulin per day for glycemic control have been established; use is supported by evidence from studies with other insulin human in pediatric patients with type 1 diabetes mellitus and from studies in adults with diabetes mellitus. Although Novolin(R) 70/30 insulin isophane human-insulin human mixture injectable suspension is labeled for use in pediatric patients with diabetes mellitus, the manufacturer of Humulin(R) 70/30 isophane insulin human-insulin human mixture injectable suspension states that the safety and effectiveness of Humulin(R) 70/30 have not been established in pediatric patients. Safety and effectiveness of insulin human dry powder for inhalation have not been established in pediatric patients.
While available studies cannot definitely establish the absence of risk, published data from retrospective studies, open-label, randomized, parallel studies and meta-analyses over decades have not established an association with insulin human injection use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes. There is limited available data on the use of insulin human dry powder for inhalation in pregnant women; data are insufficient to determine drug-associated risks for adverse developmental outcomes. All available studies have methodological limitations, including lack of blinding, unclear methods or randomization, and small sample size.
Animal reproduction studies have not been performed with insulin human for injection. In animal reproduction studies with insulin human dry powder for inhalation, there were no adverse developmental outcomes with subcutaneous administration of carrier particles (vehicle without insulin) to pregnant rats during organogenesis at doses 21 times the human exposure at a daily dose of 99 mg, based on AUC.
There are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy. Poorly controlled diabetes mellitus in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes mellitus in pregnancy increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.
Available data from published literature suggests that exogenously administered human insulin is distributed into human milk. There are no adverse effects reported in breast-fed infants in the literature. There are no data on the effects of exogenous human insulin products on milk production.
There are no data on the presence of insulin human dry powder for inhalation in human milk, the effects on the breast-fed infant, or the effects on milk production; carrier particles administered subcutaneously are present in rat milk at approximately 10% of the maternal exposure. Based on the results of the rat study, it is highly likely that both insulin human and the carrier particles are distributed into human milk. Potential adverse effects that are related to inhalation administration of insulin human are unlikely to be associated with potential exposure through breast milk.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for insulin human and any potential adverse effects on the breast-fed child from insulin human or the underlying maternal condition.
The manufacturers of insulin human make no specific dosage recommendations for geriatric patients. Elderly patients may be at increased risk of hypoglycemia due to co-morbid disease states and concomitant medications.
Caution should be exercised with using insulin human regular U-500 in geriatric patients; the initial dosage, dosage increments, and maintenance dosage should be conservative to avoid hypoglycemia.
The effect of age on the pharmacokinetics and pharmacodynamics of insulin human has not been established. Elderly patients may be at increased risk of hypoglycemia due to co-morbid disease states and concomitant medications. Caution should be exercised with using insulin human regular U-500 in geriatric patients; in geriatric patients, the initial dosage, dose increments, and maintenance dosage should be conservative to avoid hypoglycemia.
In clinical trials, 18 of 1285 patients (1.4%) with type 1 diabetes mellitus and 151 of 635 patients (24%) with type 2 diabetes mellitus treated with insulin human (Novolin(R) R) were >=65 years of age. Conclusions are limited regarding the efficacy and safety in patients >=65 years of age.
In clinical trials with insulin human dry powder for inhalation, 671 patients (12%) were >=65 years of age, of which 42 (0.8%) were >=75 years of age. In these studies, 381 (13%) of insulin human dry powder for inhalation-treated patients were >=65 years of age, of which 20 (0.7%) were >=75 years of age. No overall differences in effectiveness with insulin human dry powder for inhalation have been observed between patients >=65 years of age and younger adult patients. Clinical studies with insulin human dry powder for inhalation did not include sufficient numbers of patients 65 years of age and older to determine whether there were differences in safety between these and younger patients.
ICD codes
| Code | Type | Description |
|---|---|---|
| Diabetes mellitus with severe insulin resistance | ||
| E08 | ICD10CM | Diabetes mellitus due to underlying condition |
| E08.0 | ICD10CM | Diabetes mellitus due to underlying condition with hyperosmolarity |
| E08.00 | ICD10CM | Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
| E08.01 | ICD10CM | Diabetes mellitus due to underlying condition with hyperosmolarity with coma |
| E08.1 | ICD10CM | Diabetes mellitus due to underlying condition with ketoacidosis |
| E08.10 | ICD10CM | Diabetes mellitus due to underlying condition with ketoacidosis without coma |
| E08.11 | ICD10CM | Diabetes mellitus due to underlying condition with ketoacidosis with coma |
| E08.2 | ICD10CM | Diabetes mellitus due to underlying condition with kidney complications |
| E08.21 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic nephropathy |
| E08.22 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic chronic kidney disease |
| E08.29 | ICD10CM | Diabetes mellitus due to underlying condition with other diabetic kidney complication |
| E08.3 | ICD10CM | Diabetes mellitus due to underlying condition with ophthalmic complications |
| E08.31 | ICD10CM | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy |
| E08.311 | ICD10CM | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema |
| E08.319 | ICD10CM | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema |
| E08.32 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy |
| E08.321 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema |
| E08.3211 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye |
| E08.3212 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye |
| E08.3213 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
| E08.3219 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E08.329 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema |
| E08.3291 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye |
| E08.3292 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye |
| E08.3293 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E08.3299 | ICD10CM | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E08.33 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy |
| E08.331 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema |
| E08.3311 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
| E08.3312 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
| E08.3313 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
| E08.3319 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E08.339 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema |
| E08.3391 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E08.3392 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
| E08.3393 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E08.3399 | ICD10CM | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E08.34 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy |
| E08.341 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema |
| E08.3411 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye |
| E08.3412 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye |
| E08.3413 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
| E08.3419 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E08.349 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema |
| E08.3491 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye |
| E08.3492 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye |
| E08.3493 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
| E08.3499 | ICD10CM | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E08.35 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy |
| E08.351 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema |
| E08.3511 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye |
| E08.3512 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye |
| E08.3513 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral |
| E08.3519 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye |
| E08.352 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
| E08.3521 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
| E08.3522 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
| E08.3523 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
| E08.3529 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
| E08.353 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
| E08.3531 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
| E08.3532 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
| E08.3533 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
| E08.3539 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
| E08.354 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
| E08.3541 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E08.3542 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
| E08.3543 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E08.3549 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
| E08.355 | ICD10CM | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy |
| E08.3551 | ICD10CM | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye |
| E08.3552 | ICD10CM | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye |
| E08.3553 | ICD10CM | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral |
| E08.3559 | ICD10CM | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye |
| E08.359 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema |
| E08.3591 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye |
| E08.3592 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye |
| E08.3593 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral |
| E08.3599 | ICD10CM | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye |
| E08.36 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic cataract |
| E08.37 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment |
| E08.37x1 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye |
| E08.37x2 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye |
| E08.37x3 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral |
| E08.37x9 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye |
| E08.39 | ICD10CM | Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication |
| E08.4 | ICD10CM | Diabetes mellitus due to underlying condition with neurological complications |
| E08.40 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified |
| E08.41 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic mononeuropathy |
| E08.42 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic polyneuropathy |
| E08.43 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy |
| E08.44 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic amyotrophy |
| E08.49 | ICD10CM | Diabetes mellitus due to underlying condition with other diabetic neurological complication |
| E08.5 | ICD10CM | Diabetes mellitus due to underlying condition with circulatory complications |
| E08.51 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene |
| E08.52 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene |
| E08.59 | ICD10CM | Diabetes mellitus due to underlying condition with other circulatory complications |
| E08.6 | ICD10CM | Diabetes mellitus due to underlying condition with other specified complications |
| E08.61 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic arthropathy |
| E08.610 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy |
| E08.618 | ICD10CM | Diabetes mellitus due to underlying condition with other diabetic arthropathy |
| E08.62 | ICD10CM | Diabetes mellitus due to underlying condition with skin complications |
| E08.620 | ICD10CM | Diabetes mellitus due to underlying condition with diabetic dermatitis |
| E08.621 | ICD10CM | Diabetes mellitus due to underlying condition with foot ulcer |
| E08.622 | ICD10CM | Diabetes mellitus due to underlying condition with other skin ulcer |
| E08.628 | ICD10CM | Diabetes mellitus due to underlying condition with other skin complications |
| E08.63 | ICD10CM | Diabetes mellitus due to underlying condition with oral complications |
| E08.630 | ICD10CM | Diabetes mellitus due to underlying condition with periodontal disease |
| E08.638 | ICD10CM | Diabetes mellitus due to underlying condition with other oral complications |
| E08.64 | ICD10CM | Diabetes mellitus due to underlying condition with hypoglycemia |
| E08.641 | ICD10CM | Diabetes mellitus due to underlying condition with hypoglycemia with coma |
| E08.649 | ICD10CM | Diabetes mellitus due to underlying condition with hypoglycemia without coma |
| E08.65 | ICD10CM | Diabetes mellitus due to underlying condition with hyperglycemia |
| E08.69 | ICD10CM | Diabetes mellitus due to underlying condition with other specified complication |
| E08.8 | ICD10CM | Diabetes mellitus due to underlying condition with unspecified complications |
| E08.9 | ICD10CM | Diabetes mellitus due to underlying condition without complications |
| E09 | ICD10CM | Drug or chemical induced diabetes mellitus |
| E09.0 | ICD10CM | Drug or chemical induced diabetes mellitus with hyperosmolarity |
| E09.00 | ICD10CM | Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
| E09.01 | ICD10CM | Drug or chemical induced diabetes mellitus with hyperosmolarity with coma |
| E09.1 | ICD10CM | Drug or chemical induced diabetes mellitus with ketoacidosis |
| E09.10 | ICD10CM | Drug or chemical induced diabetes mellitus with ketoacidosis without coma |
| E09.11 | ICD10CM | Drug or chemical induced diabetes mellitus with ketoacidosis with coma |
| E09.2 | ICD10CM | Drug or chemical induced diabetes mellitus with kidney complications |
| E09.21 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic nephropathy |
| E09.22 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease |
| E09.29 | ICD10CM | Drug or chemical induced diabetes mellitus with other diabetic kidney complication |
| E09.3 | ICD10CM | Drug or chemical induced diabetes mellitus with ophthalmic complications |
| E09.31 | ICD10CM | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy |
| E09.311 | ICD10CM | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema |
| E09.319 | ICD10CM | Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema |
| E09.32 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy |
| E09.321 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
| E09.3211 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
| E09.3212 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
| E09.3213 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
| E09.3219 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E09.329 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
| E09.3291 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
| E09.3292 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
| E09.3293 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E09.3299 | ICD10CM | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E09.33 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy |
| E09.331 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
| E09.3311 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
| E09.3312 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
| E09.3313 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
| E09.3319 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E09.339 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
| E09.3391 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E09.3392 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
| E09.3393 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E09.3399 | ICD10CM | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E09.34 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy |
| E09.341 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
| E09.3411 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
| E09.3412 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
| E09.3413 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
| E09.3419 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E09.349 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
| E09.3491 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
| E09.3492 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
| E09.3493 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
| E09.3499 | ICD10CM | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E09.35 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy |
| E09.351 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema |
| E09.3511 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
| E09.3512 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
| E09.3513 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
| E09.3519 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
| E09.352 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
| E09.3521 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
| E09.3522 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
| E09.3523 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
| E09.3529 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
| E09.353 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
| E09.3531 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
| E09.3532 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
| E09.3533 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
| E09.3539 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
| E09.354 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
| E09.3541 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E09.3542 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
| E09.3543 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E09.3549 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
| E09.355 | ICD10CM | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy |
| E09.3551 | ICD10CM | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
| E09.3552 | ICD10CM | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
| E09.3553 | ICD10CM | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
| E09.3559 | ICD10CM | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
| E09.359 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema |
| E09.3591 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
| E09.3592 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
| E09.3593 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
| E09.3599 | ICD10CM | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
| E09.36 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic cataract |
| E09.37 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment |
| E09.37x1 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
| E09.37x2 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
| E09.37x3 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
| E09.37x9 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
| E09.39 | ICD10CM | Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication |
| E09.4 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications |
| E09.40 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified |
| E09.41 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy |
| E09.42 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy |
| E09.43 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy |
| E09.44 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy |
| E09.49 | ICD10CM | Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication |
| E09.5 | ICD10CM | Drug or chemical induced diabetes mellitus with circulatory complications |
| E09.51 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene |
| E09.52 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene |
| E09.59 | ICD10CM | Drug or chemical induced diabetes mellitus with other circulatory complications |
| E09.6 | ICD10CM | Drug or chemical induced diabetes mellitus with other specified complications |
| E09.61 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic arthropathy |
| E09.610 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy |
| E09.618 | ICD10CM | Drug or chemical induced diabetes mellitus with other diabetic arthropathy |
| E09.62 | ICD10CM | Drug or chemical induced diabetes mellitus with skin complications |
| E09.620 | ICD10CM | Drug or chemical induced diabetes mellitus with diabetic dermatitis |
| E09.621 | ICD10CM | Drug or chemical induced diabetes mellitus with foot ulcer |
| E09.622 | ICD10CM | Drug or chemical induced diabetes mellitus with other skin ulcer |
| E09.628 | ICD10CM | Drug or chemical induced diabetes mellitus with other skin complications |
| E09.63 | ICD10CM | Drug or chemical induced diabetes mellitus with oral complications |
| E09.630 | ICD10CM | Drug or chemical induced diabetes mellitus with periodontal disease |
| E09.638 | ICD10CM | Drug or chemical induced diabetes mellitus with other oral complications |
| E09.64 | ICD10CM | Drug or chemical induced diabetes mellitus with hypoglycemia |
| E09.641 | ICD10CM | Drug or chemical induced diabetes mellitus with hypoglycemia with coma |
| E09.649 | ICD10CM | Drug or chemical induced diabetes mellitus with hypoglycemia without coma |
| E09.65 | ICD10CM | Drug or chemical induced diabetes mellitus with hyperglycemia |
| E09.69 | ICD10CM | Drug or chemical induced diabetes mellitus with other specified complication |
| E09.8 | ICD10CM | Drug or chemical induced diabetes mellitus with unspecified complications |
| E09.9 | ICD10CM | Drug or chemical induced diabetes mellitus without complications |
| E10 | ICD10CM | Type 1 diabetes mellitus |
| E10.1 | ICD10CM | Type 1 diabetes mellitus with ketoacidosis |
| E10.10 | ICD10CM | Type 1 diabetes mellitus with ketoacidosis without coma |
| E10.11 | ICD10CM | Type 1 diabetes mellitus with ketoacidosis with coma |
| E10.2 | ICD10CM | Type 1 diabetes mellitus with kidney complications |
| E10.21 | ICD10CM | Type 1 diabetes mellitus with diabetic nephropathy |
| E10.22 | ICD10CM | Type 1 diabetes mellitus with diabetic chronic kidney disease |
| E10.29 | ICD10CM | Type 1 diabetes mellitus with other diabetic kidney complication |
| E10.3 | ICD10CM | Type 1 diabetes mellitus with ophthalmic complications |
| E10.31 | ICD10CM | Type 1 diabetes mellitus with unspecified diabetic retinopathy |
| E10.311 | ICD10CM | Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema |
| E10.319 | ICD10CM | Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema |
| E10.32 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy |
| E10.321 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
| E10.3211 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
| E10.3212 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
| E10.3213 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
| E10.3219 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E10.329 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
| E10.3291 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
| E10.3292 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
| E10.3293 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E10.3299 | ICD10CM | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E10.33 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy |
| E10.331 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
| E10.3311 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
| E10.3312 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
| E10.3313 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
| E10.3319 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E10.339 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
| E10.3391 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E10.3392 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
| E10.3393 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E10.3399 | ICD10CM | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E10.34 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy |
| E10.341 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
| E10.3411 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
| E10.3412 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
| E10.3413 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
| E10.3419 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E10.349 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
| E10.3491 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
| E10.3492 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
| E10.3493 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
| E10.3499 | ICD10CM | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E10.35 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy |
| E10.351 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema |
| E10.3511 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
| E10.3512 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
| E10.3513 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
| E10.3519 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
| E10.352 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
| E10.3521 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
| E10.3522 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
| E10.3523 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
| E10.3529 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
| E10.353 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
| E10.3531 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
| E10.3532 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
| E10.3533 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
| E10.3539 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
| E10.354 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
| E10.3541 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E10.3542 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
| E10.3543 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E10.3549 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
| E10.355 | ICD10CM | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy |
| E10.3551 | ICD10CM | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
| E10.3552 | ICD10CM | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
| E10.3553 | ICD10CM | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
| E10.3559 | ICD10CM | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
| E10.359 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema |
| E10.3591 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
| E10.3592 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
| E10.3593 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
| E10.3599 | ICD10CM | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
| E10.36 | ICD10CM | Type 1 diabetes mellitus with diabetic cataract |
| E10.37 | ICD10CM | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment |
| E10.37x1 | ICD10CM | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
| E10.37x2 | ICD10CM | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
| E10.37x3 | ICD10CM | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
| E10.37x9 | ICD10CM | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
| E10.39 | ICD10CM | Type 1 diabetes mellitus with other diabetic ophthalmic complication |
| E10.4 | ICD10CM | Type 1 diabetes mellitus with neurological complications |
| E10.40 | ICD10CM | Type 1 diabetes mellitus with diabetic neuropathy, unspecified |
| E10.41 | ICD10CM | Type 1 diabetes mellitus with diabetic mononeuropathy |
| E10.42 | ICD10CM | Type 1 diabetes mellitus with diabetic polyneuropathy |
| E10.43 | ICD10CM | Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy |
| E10.44 | ICD10CM | Type 1 diabetes mellitus with diabetic amyotrophy |
| E10.49 | ICD10CM | Type 1 diabetes mellitus with other diabetic neurological complication |
| E10.5 | ICD10CM | Type 1 diabetes mellitus with circulatory complications |
| E10.51 | ICD10CM | Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene |
| E10.52 | ICD10CM | Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene |
| E10.59 | ICD10CM | Type 1 diabetes mellitus with other circulatory complications |
| E10.6 | ICD10CM | Type 1 diabetes mellitus with other specified complications |
| E10.61 | ICD10CM | Type 1 diabetes mellitus with diabetic arthropathy |
| E10.610 | ICD10CM | Type 1 diabetes mellitus with diabetic neuropathic arthropathy |
| E10.618 | ICD10CM | Type 1 diabetes mellitus with other diabetic arthropathy |
| E10.62 | ICD10CM | Type 1 diabetes mellitus with skin complications |
| E10.620 | ICD10CM | Type 1 diabetes mellitus with diabetic dermatitis |
| E10.621 | ICD10CM | Type 1 diabetes mellitus with foot ulcer |
| E10.622 | ICD10CM | Type 1 diabetes mellitus with other skin ulcer |
| E10.628 | ICD10CM | Type 1 diabetes mellitus with other skin complications |
| E10.63 | ICD10CM | Type 1 diabetes mellitus with oral complications |
| E10.630 | ICD10CM | Type 1 diabetes mellitus with periodontal disease |
| E10.638 | ICD10CM | Type 1 diabetes mellitus with other oral complications |
| E10.64 | ICD10CM | Type 1 diabetes mellitus with hypoglycemia |
| E10.641 | ICD10CM | Type 1 diabetes mellitus with hypoglycemia with coma |
| E10.649 | ICD10CM | Type 1 diabetes mellitus with hypoglycemia without coma |
| E10.65 | ICD10CM | Type 1 diabetes mellitus with hyperglycemia |
| E10.69 | ICD10CM | Type 1 diabetes mellitus with other specified complication |
| E10.8 | ICD10CM | Type 1 diabetes mellitus with unspecified complications |
| E10.9 | ICD10CM | Type 1 diabetes mellitus without complications |
| E11 | ICD10CM | Type 2 diabetes mellitus |
| E11.0 | ICD10CM | Type 2 diabetes mellitus with hyperosmolarity |
| E11.00 | ICD10CM | Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
| E11.01 | ICD10CM | Type 2 diabetes mellitus with hyperosmolarity with coma |
| E11.1 | ICD10CM | Type 2 diabetes mellitus with ketoacidosis |
| E11.10 | ICD10CM | Type 2 diabetes mellitus with ketoacidosis without coma |
| E11.11 | ICD10CM | Type 2 diabetes mellitus with ketoacidosis with coma |
| E11.2 | ICD10CM | Type 2 diabetes mellitus with kidney complications |
| E11.21 | ICD10CM | Type 2 diabetes mellitus with diabetic nephropathy |
| E11.22 | ICD10CM | Type 2 diabetes mellitus with diabetic chronic kidney disease |
| E11.29 | ICD10CM | Type 2 diabetes mellitus with other diabetic kidney complication |
| E11.3 | ICD10CM | Type 2 diabetes mellitus with ophthalmic complications |
| E11.31 | ICD10CM | Type 2 diabetes mellitus with unspecified diabetic retinopathy |
| E11.311 | ICD10CM | Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema |
| E11.319 | ICD10CM | Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema |
| E11.32 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy |
| E11.321 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
| E11.3211 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
| E11.3212 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
| E11.3213 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
| E11.3219 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E11.329 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
| E11.3291 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
| E11.3292 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
| E11.3293 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E11.3299 | ICD10CM | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E11.33 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy |
| E11.331 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
| E11.3311 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
| E11.3312 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
| E11.3313 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
| E11.3319 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E11.339 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
| E11.3391 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E11.3392 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
| E11.3393 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E11.3399 | ICD10CM | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E11.34 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy |
| E11.341 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
| E11.3411 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
| E11.3412 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
| E11.3413 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
| E11.3419 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E11.349 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
| E11.3491 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
| E11.3492 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
| E11.3493 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
| E11.3499 | ICD10CM | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E11.35 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy |
| E11.351 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema |
| E11.3511 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
| E11.3512 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
| E11.3513 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
| E11.3519 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
| E11.352 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
| E11.3521 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
| E11.3522 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
| E11.3523 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
| E11.3529 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
| E11.353 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
| E11.3531 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
| E11.3532 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
| E11.3533 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
| E11.3539 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
| E11.354 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
| E11.3541 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E11.3542 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
| E11.3543 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E11.3549 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
| E11.355 | ICD10CM | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy |
| E11.3551 | ICD10CM | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
| E11.3552 | ICD10CM | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
| E11.3553 | ICD10CM | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
| E11.3559 | ICD10CM | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
| E11.359 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema |
| E11.3591 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
| E11.3592 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
| E11.3593 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
| E11.3599 | ICD10CM | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
| E11.36 | ICD10CM | Type 2 diabetes mellitus with diabetic cataract |
| E11.37 | ICD10CM | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment |
| E11.37x1 | ICD10CM | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
| E11.37x2 | ICD10CM | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
| E11.37x3 | ICD10CM | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
| E11.37x9 | ICD10CM | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
| E11.39 | ICD10CM | Type 2 diabetes mellitus with other diabetic ophthalmic complication |
| E11.4 | ICD10CM | Type 2 diabetes mellitus with neurological complications |
| E11.40 | ICD10CM | Type 2 diabetes mellitus with diabetic neuropathy, unspecified |
| E11.41 | ICD10CM | Type 2 diabetes mellitus with diabetic mononeuropathy |
| E11.42 | ICD10CM | Type 2 diabetes mellitus with diabetic polyneuropathy |
| E11.43 | ICD10CM | Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy |
| E11.44 | ICD10CM | Type 2 diabetes mellitus with diabetic amyotrophy |
| E11.49 | ICD10CM | Type 2 diabetes mellitus with other diabetic neurological complication |
| E11.5 | ICD10CM | Type 2 diabetes mellitus with circulatory complications |
| E11.51 | ICD10CM | Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene |
| E11.52 | ICD10CM | Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene |
| E11.59 | ICD10CM | Type 2 diabetes mellitus with other circulatory complications |
| E11.6 | ICD10CM | Type 2 diabetes mellitus with other specified complications |
| E11.61 | ICD10CM | Type 2 diabetes mellitus with diabetic arthropathy |
| E11.610 | ICD10CM | Type 2 diabetes mellitus with diabetic neuropathic arthropathy |
| E11.618 | ICD10CM | Type 2 diabetes mellitus with other diabetic arthropathy |
| E11.62 | ICD10CM | Type 2 diabetes mellitus with skin complications |
| E11.620 | ICD10CM | Type 2 diabetes mellitus with diabetic dermatitis |
| E11.621 | ICD10CM | Type 2 diabetes mellitus with foot ulcer |
| E11.622 | ICD10CM | Type 2 diabetes mellitus with other skin ulcer |
| E11.628 | ICD10CM | Type 2 diabetes mellitus with other skin complications |
| E11.63 | ICD10CM | Type 2 diabetes mellitus with oral complications |
| E11.630 | ICD10CM | Type 2 diabetes mellitus with periodontal disease |
| E11.638 | ICD10CM | Type 2 diabetes mellitus with other oral complications |
| E11.64 | ICD10CM | Type 2 diabetes mellitus with hypoglycemia |
| E11.641 | ICD10CM | Type 2 diabetes mellitus with hypoglycemia with coma |
| E11.649 | ICD10CM | Type 2 diabetes mellitus with hypoglycemia without coma |
| E11.65 | ICD10CM | Type 2 diabetes mellitus with hyperglycemia |
| E11.69 | ICD10CM | Type 2 diabetes mellitus with other specified complication |
| E11.8 | ICD10CM | Type 2 diabetes mellitus with unspecified complications |
| E11.9 | ICD10CM | Type 2 diabetes mellitus without complications |
| E13 | ICD10CM | Other specified diabetes mellitus |
| E13.0 | ICD10CM | Other specified diabetes mellitus with hyperosmolarity |
| E13.00 | ICD10CM | Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHc) |
| E13.01 | ICD10CM | Other specified diabetes mellitus with hyperosmolarity with coma |
| E13.1 | ICD10CM | Other specified diabetes mellitus with ketoacidosis |
| E13.10 | ICD10CM | Other specified diabetes mellitus with ketoacidosis without coma |
| E13.11 | ICD10CM | Other specified diabetes mellitus with ketoacidosis with coma |
| E13.2 | ICD10CM | Other specified diabetes mellitus with kidney complications |
| E13.21 | ICD10CM | Other specified diabetes mellitus with diabetic nephropathy |
| E13.22 | ICD10CM | Other specified diabetes mellitus with diabetic chronic kidney disease |
| E13.29 | ICD10CM | Other specified diabetes mellitus with other diabetic kidney complication |
| E13.3 | ICD10CM | Other specified diabetes mellitus with ophthalmic complications |
| E13.31 | ICD10CM | Other specified diabetes mellitus with unspecified diabetic retinopathy |
| E13.311 | ICD10CM | Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema |
| E13.319 | ICD10CM | Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema |
| E13.32 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy |
| E13.321 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema |
| E13.3211 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye |
| E13.3212 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye |
| E13.3213 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
| E13.3219 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E13.329 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema |
| E13.3291 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye |
| E13.3292 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye |
| E13.3293 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E13.3299 | ICD10CM | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E13.33 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy |
| E13.331 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema |
| E13.3311 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
| E13.3312 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
| E13.3313 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
| E13.3319 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E13.339 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema |
| E13.3391 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E13.3392 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
| E13.3393 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E13.3399 | ICD10CM | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E13.34 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy |
| E13.341 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema |
| E13.3411 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye |
| E13.3412 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye |
| E13.3413 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
| E13.3419 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E13.349 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema |
| E13.3491 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye |
| E13.3492 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye |
| E13.3493 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral |
| E13.3499 | ICD10CM | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E13.35 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy |
| E13.351 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema |
| E13.3511 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye |
| E13.3512 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye |
| E13.3513 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral |
| E13.3519 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye |
| E13.352 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula |
| E13.3521 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye |
| E13.3522 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye |
| E13.3523 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral |
| E13.3529 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye |
| E13.353 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula |
| E13.3531 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
| E13.3532 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye |
| E13.3533 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
| E13.3539 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye |
| E13.354 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment |
| E13.3541 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E13.3542 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye |
| E13.3543 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E13.3549 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye |
| E13.355 | ICD10CM | Other specified diabetes mellitus with stable proliferative diabetic retinopathy |
| E13.3551 | ICD10CM | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye |
| E13.3552 | ICD10CM | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye |
| E13.3553 | ICD10CM | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral |
| E13.3559 | ICD10CM | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye |
| E13.359 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema |
| E13.3591 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
| E13.3592 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye |
| E13.3593 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
| E13.3599 | ICD10CM | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye |
| E13.36 | ICD10CM | Other specified diabetes mellitus with diabetic cataract |
| E13.37 | ICD10CM | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment |
| E13.37x1 | ICD10CM | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye |
| E13.37x2 | ICD10CM | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye |
| E13.37x3 | ICD10CM | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral |
| E13.37x9 | ICD10CM | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye |
| E13.39 | ICD10CM | Other specified diabetes mellitus with other diabetic ophthalmic complication |
| E13.4 | ICD10CM | Other specified diabetes mellitus with neurological complications |
| E13.40 | ICD10CM | Other specified diabetes mellitus with diabetic neuropathy, unspecified |
| E13.41 | ICD10CM | Other specified diabetes mellitus with diabetic mononeuropathy |
| E13.42 | ICD10CM | Other specified diabetes mellitus with diabetic polyneuropathy |
| E13.43 | ICD10CM | Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy |
| E13.44 | ICD10CM | Other specified diabetes mellitus with diabetic amyotrophy |
| E13.49 | ICD10CM | Other specified diabetes mellitus with other diabetic neurological complication |
| E13.5 | ICD10CM | Other specified diabetes mellitus with circulatory complications |
| E13.51 | ICD10CM | Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene |
| E13.52 | ICD10CM | Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene |
| E13.59 | ICD10CM | Other specified diabetes mellitus with other circulatory complications |
| E13.6 | ICD10CM | Other specified diabetes mellitus with other specified complications |
| E13.61 | ICD10CM | Other specified diabetes mellitus with diabetic arthropathy |
| E13.610 | ICD10CM | Other specified diabetes mellitus with diabetic neuropathic arthropathy |
| E13.618 | ICD10CM | Other specified diabetes mellitus with other diabetic arthropathy |
| E13.62 | ICD10CM | Other specified diabetes mellitus with skin complications |
| E13.620 | ICD10CM | Other specified diabetes mellitus with diabetic dermatitis |
| E13.621 | ICD10CM | Other specified diabetes mellitus with foot ulcer |
| E13.622 | ICD10CM | Other specified diabetes mellitus with other skin ulcer |
| E13.628 | ICD10CM | Other specified diabetes mellitus with other skin complications |
| E13.63 | ICD10CM | Other specified diabetes mellitus with oral complications |
| E13.630 | ICD10CM | Other specified diabetes mellitus with periodontal disease |
| E13.638 | ICD10CM | Other specified diabetes mellitus with other oral complications |
| E13.64 | ICD10CM | Other specified diabetes mellitus with hypoglycemia |
| E13.641 | ICD10CM | Other specified diabetes mellitus with hypoglycemia with coma |
| E13.649 | ICD10CM | Other specified diabetes mellitus with hypoglycemia without coma |
| E13.65 | ICD10CM | Other specified diabetes mellitus with hyperglycemia |
| E13.69 | ICD10CM | Other specified diabetes mellitus with other specified complication |
| E13.8 | ICD10CM | Other specified diabetes mellitus with unspecified complications |
| E13.9 | ICD10CM | Other specified diabetes mellitus without complications |
| O24 | ICD10CM | Diabetes mellitus in pregnancy, childbirth, and the puerperium |
| O24.0 | ICD10CM | Pre-existing type 1 diabetes mellitus, in pregnancy, childbirth and the puerperium |
| O24.01 | ICD10CM | Pre-existing type 1 diabetes mellitus, in pregnancy |
| O24.011 | ICD10CM | Pre-existing type 1 diabetes mellitus, in pregnancy, first trimester |
| O24.012 | ICD10CM | Pre-existing type 1 diabetes mellitus, in pregnancy, second trimester |
| O24.013 | ICD10CM | Pre-existing type 1 diabetes mellitus, in pregnancy, third trimester |
| O24.019 | ICD10CM | Pre-existing type 1 diabetes mellitus, in pregnancy, unspecified trimester |
| O24.02 | ICD10CM | Pre-existing type 1 diabetes mellitus, in childbirth |
| O24.03 | ICD10CM | Pre-existing type 1 diabetes mellitus, in the puerperium |
| O24.1 | ICD10CM | Pre-existing type 2 diabetes mellitus, in pregnancy, childbirth and the puerperium |
| O24.11 | ICD10CM | Pre-existing type 2 diabetes mellitus, in pregnancy |
| O24.111 | ICD10CM | Pre-existing type 2 diabetes mellitus, in pregnancy, first trimester |
| O24.112 | ICD10CM | Pre-existing type 2 diabetes mellitus, in pregnancy, second trimester |
| O24.113 | ICD10CM | Pre-existing type 2 diabetes mellitus, in pregnancy, third trimester |
| O24.119 | ICD10CM | Pre-existing type 2 diabetes mellitus, in pregnancy, unspecified trimester |
| O24.12 | ICD10CM | Pre-existing type 2 diabetes mellitus, in childbirth |
| O24.13 | ICD10CM | Pre-existing type 2 diabetes mellitus, in the puerperium |
| O24.3 | ICD10CM | Unspecified pre-existing diabetes mellitus in pregnancy, childbirth and the puerperium |
| O24.31 | ICD10CM | Unspecified pre-existing diabetes mellitus in pregnancy |
| O24.311 | ICD10CM | Unspecified pre-existing diabetes mellitus in pregnancy, first trimester |
| O24.312 | ICD10CM | Unspecified pre-existing diabetes mellitus in pregnancy, second trimester |
| O24.313 | ICD10CM | Unspecified pre-existing diabetes mellitus in pregnancy, third trimester |
| O24.319 | ICD10CM | Unspecified pre-existing diabetes mellitus in pregnancy, unspecified trimester |
| O24.32 | ICD10CM | Unspecified pre-existing diabetes mellitus in childbirth |
| O24.33 | ICD10CM | Unspecified pre-existing diabetes mellitus in the puerperium |
| O24.4 | ICD10CM | Gestational diabetes mellitus |
| O24.41 | ICD10CM | Gestational diabetes mellitus in pregnancy |
| O24.414 | ICD10CM | Gestational diabetes mellitus in pregnancy, insulin controlled |
| O24.419 | ICD10CM | Gestational diabetes mellitus in pregnancy, unspecified control |
| O24.42 | ICD10CM | Gestational diabetes mellitus in childbirth |
| O24.424 | ICD10CM | Gestational diabetes mellitus in childbirth, insulin controlled |
| O24.429 | ICD10CM | Gestational diabetes mellitus in childbirth, unspecified control |
| O24.43 | ICD10CM | Gestational diabetes mellitus in the puerperium |
| O24.434 | ICD10CM | Gestational diabetes mellitus in the puerperium, insulin controlled |
| O24.439 | ICD10CM | Gestational diabetes mellitus in the puerperium, unspecified control |
| O24.8 | ICD10CM | Other pre-existing diabetes mellitus in pregnancy, childbirth, and the puerperium |
| O24.81 | ICD10CM | Other pre-existing diabetes mellitus in pregnancy |
| O24.811 | ICD10CM | Other pre-existing diabetes mellitus in pregnancy, first trimester |
| O24.812 | ICD10CM | Other pre-existing diabetes mellitus in pregnancy, second trimester |
| O24.813 | ICD10CM | Other pre-existing diabetes mellitus in pregnancy, third trimester |
| O24.819 | ICD10CM | Other pre-existing diabetes mellitus in pregnancy, unspecified trimester |
| O24.82 | ICD10CM | Other pre-existing diabetes mellitus in childbirth |
| O24.83 | ICD10CM | Other pre-existing diabetes mellitus in the puerperium |
| O24.9 | ICD10CM | Unspecified diabetes mellitus in pregnancy, childbirth and the puerperium |
| O24.91 | ICD10CM | Unspecified diabetes mellitus in pregnancy |
| O24.911 | ICD10CM | Unspecified diabetes mellitus in pregnancy, first trimester |
| O24.912 | ICD10CM | Unspecified diabetes mellitus in pregnancy, second trimester |
| O24.913 | ICD10CM | Unspecified diabetes mellitus in pregnancy, third trimester |
| O24.919 | ICD10CM | Unspecified diabetes mellitus in pregnancy, unspecified trimester |
| O24.92 | ICD10CM | Unspecified diabetes mellitus in childbirth |
| O24.93 | ICD10CM | Unspecified diabetes mellitus in the puerperium |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.